(NASDAQ:ECOR), ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY […]
(NASDAQ:HNRG), – Q3 Total Revenue up 40% YoY to $146.8 Million –– Q3 Net Income Increases to $23.9 Million or $0.56 Earnings per Share –– Q3 Operating Cash Flow of $23.2 Million –– Q3 Adjusted EBITDA up 1.6x to $24.9 Million –– Filed ERAS Application for 525MW Gas Generation Expansion – TERRE HAUTE, Ind., Nov.
(NASDAQ:MLYS), – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused
(NASDAQ:BEEP), –Contract Volumes Continued to Increase, Up 8.0% Year-to-Date– –Asset Rotation Strategy On Track; Expect To Have Approximately $30 Million of Non-Core Assets Under Contract Or Sold By The End of 2025– –Recently Completed $100 Million Asset-Backed Securitization Increases Capital Flexibility and Facilitates Portfolio Optimization– –Conference Call Will be Held November 10th at 4:30 PM
(NasdaqGM:GEMI), NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Gemini Space Station, Inc. (Gemini) (NASDAQ: GEMI) today reported its third quarter 2025 financial results in a shareholder letter which can be found on its Investor Relations website at https://investors.gemini.com. Management will host a conference call at 5:00 pm E.T. today to discuss the results. The
(NASDAQ:ANNX), Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barre Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline
(NASDAQ:HFFG), Net Revenue increased 2.9% to $307.0 millionGAAP Net Loss decreased 77.2% to $0.9 millionAdj. EBITDA up 42% to $11.7 million LAS VEGAS, Nov. 10, 2025 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading distributor of international foodservice solutions to Asian restaurants and other businesses across the
(NASDAQ:OM), SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2025 and revised its 2025 revenue guidance. Third Quarter and Recent Highlights Net
(NYSE MKT:STXS), ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX(TM). GenesisX is the latest advance in endovascular surgical robotics, building
(NASDAQ:VTSI), CHANDLER, Ariz., Nov. 10, 2025 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the third quarter ended September 30, 2025. The financial statements are available on VirTra's website and here. Third Quarter 2025 and Recent Operational Highlights Bookings